Sirona Biochem Announces Resignation of Board Director
VANCOUVER, BC --(Marketwired - October 27, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM)
(FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of
Mr. David Moore from the board of directors due to conflicting commitments.
"We are very thankful to Mr. Moore for his contributions and guidance during his time on our board and wish him much success
in his new position," said Dr. Howard Verrico, CEO. "At this time the Company will remain with a vacancy on the board until a
suitable replacement is found."
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum
revenue potential.
Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific
awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts
may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve
known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results,
performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking
statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements
about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory
approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its
products that could delay or prevent product development or commercialization; the scope and validity of patent protection for
its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to
support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required
by law.